TrialCancer2016

Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.

Gautam Borthakur et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.